Assessment of walking in patients with Duchenne muscular dystrophy receiving ataluren in real clinical practice
Background. Duchenne muscular dystrophy (DMD) is an X-linked recessive disease caused by a variant in the DMD gene, leading to severe disability and death at a young age. Today, in some variants in the DMD gene, etiopathogenetic therapy is possible to increase the patient’s life expectancy and impro...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2025-04-01
|
| Series: | Нервно-мышечные болезни |
| Subjects: | |
| Online Access: | https://nmb.abvpress.ru/jour/article/view/648 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849399673804029952 |
|---|---|
| author | D. V. Aizatulina S. S. Nikitin |
| author_facet | D. V. Aizatulina S. S. Nikitin |
| author_sort | D. V. Aizatulina |
| collection | DOAJ |
| description | Background. Duchenne muscular dystrophy (DMD) is an X-linked recessive disease caused by a variant in the DMD gene, leading to severe disability and death at a young age. Today, in some variants in the DMD gene, etiopathogenetic therapy is possible to increase the patient’s life expectancy and improve his quality of life.Aim. To evaluate the dynamics of assess the dynamics of the ability to walk independently in patients with DMD caused by a nonsense variant in the DMD gene on the background of therapy with the drug ataluren.Materials and methods. The study included 9 patients with DMD caused by nonsense variants in the DMD gene. Of them, 3 patients were brothers and lost the ability to walk, 6 patients at the ambulatory stage of the disease received therapy with the drug ataluren according to the standard scheme. The six-minute walk test was chosen as the main parameter to assess the treatment efficacy in comparison with the baseline values before treatment.Results. According to the data of six-minute walk test during the observation period 5 patients taking ataluren during 18–36 months retained the ability to move independently. One patient who initially walked 12 m lost ambulation 6 months after starting ataluren therapy. Compared with 3 non-ambulatory brothers with DMD due to the DMD nonsense gene variant who did not receive ataluren, 3 younger brothers on ataluren therapy retained ambulation at an age when the older brothers had already become non-ambulatory.Conclusion. Pathogenetic therapy with the drug ataluren slows down the clinical course of DMD caused by a nonsense variant in the DMD gene with preservation of ambulatory capacity and is characterized by good tolerability. |
| format | Article |
| id | doaj-art-26ded94a8a5543ff8903e927100c6190 |
| institution | Kabale University |
| issn | 2222-8721 2413-0443 |
| language | Russian |
| publishDate | 2025-04-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Нервно-мышечные болезни |
| spelling | doaj-art-26ded94a8a5543ff8903e927100c61902025-08-20T03:38:16ZrusABV-pressНервно-мышечные болезни2222-87212413-04432025-04-01151536010.17650/2222-8721-2025-15-1-53-60408Assessment of walking in patients with Duchenne muscular dystrophy receiving ataluren in real clinical practiceD. V. Aizatulina0S. S. Nikitin1Kazan (Volga Region) Federal UniversityResearch Centre for Medical GeneticsBackground. Duchenne muscular dystrophy (DMD) is an X-linked recessive disease caused by a variant in the DMD gene, leading to severe disability and death at a young age. Today, in some variants in the DMD gene, etiopathogenetic therapy is possible to increase the patient’s life expectancy and improve his quality of life.Aim. To evaluate the dynamics of assess the dynamics of the ability to walk independently in patients with DMD caused by a nonsense variant in the DMD gene on the background of therapy with the drug ataluren.Materials and methods. The study included 9 patients with DMD caused by nonsense variants in the DMD gene. Of them, 3 patients were brothers and lost the ability to walk, 6 patients at the ambulatory stage of the disease received therapy with the drug ataluren according to the standard scheme. The six-minute walk test was chosen as the main parameter to assess the treatment efficacy in comparison with the baseline values before treatment.Results. According to the data of six-minute walk test during the observation period 5 patients taking ataluren during 18–36 months retained the ability to move independently. One patient who initially walked 12 m lost ambulation 6 months after starting ataluren therapy. Compared with 3 non-ambulatory brothers with DMD due to the DMD nonsense gene variant who did not receive ataluren, 3 younger brothers on ataluren therapy retained ambulation at an age when the older brothers had already become non-ambulatory.Conclusion. Pathogenetic therapy with the drug ataluren slows down the clinical course of DMD caused by a nonsense variant in the DMD gene with preservation of ambulatory capacity and is characterized by good tolerability.https://nmb.abvpress.ru/jour/article/view/648duchenne muscular dystrophynonsense variantnonsense mutationatalurensix-minute walk test |
| spellingShingle | D. V. Aizatulina S. S. Nikitin Assessment of walking in patients with Duchenne muscular dystrophy receiving ataluren in real clinical practice Нервно-мышечные болезни duchenne muscular dystrophy nonsense variant nonsense mutation ataluren six-minute walk test |
| title | Assessment of walking in patients with Duchenne muscular dystrophy receiving ataluren in real clinical practice |
| title_full | Assessment of walking in patients with Duchenne muscular dystrophy receiving ataluren in real clinical practice |
| title_fullStr | Assessment of walking in patients with Duchenne muscular dystrophy receiving ataluren in real clinical practice |
| title_full_unstemmed | Assessment of walking in patients with Duchenne muscular dystrophy receiving ataluren in real clinical practice |
| title_short | Assessment of walking in patients with Duchenne muscular dystrophy receiving ataluren in real clinical practice |
| title_sort | assessment of walking in patients with duchenne muscular dystrophy receiving ataluren in real clinical practice |
| topic | duchenne muscular dystrophy nonsense variant nonsense mutation ataluren six-minute walk test |
| url | https://nmb.abvpress.ru/jour/article/view/648 |
| work_keys_str_mv | AT dvaizatulina assessmentofwalkinginpatientswithduchennemusculardystrophyreceivingatalureninrealclinicalpractice AT ssnikitin assessmentofwalkinginpatientswithduchennemusculardystrophyreceivingatalureninrealclinicalpractice |